Journal
CANCER TREATMENT REVIEWS
Volume 40, Issue 1, Pages 93-101Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2013.06.002
Keywords
Non-small cell lung cancer; Acquired resistance; Tyrosine kinase inhibitors; EGFR-mutant tumors
Categories
Ask authors/readers for more resources
The discovery of mutated oncogenes has opened up a new era for the development of more effective treatments for non-small cell lung cancer patients (NSCLC) harbouring EGFR mutations. However, patients with EGFR-activating mutation ultimately develop acquired resistance (AR). Several studies have identified some of the mechanisms involved in the development of AR to EGFR tyrosine kinase inhibitors (TKI) that can be potential therapeutic strategies, although in up to 30% of cases, the underlying mechanism of AR are still unexplained. In this review we aim to summarize the main mechanisms of AR to EGFR TKI and some clinical strategies that can be used in the daily clinical practice to overcome this resistance and try to prolong the outcomes in this subgroup of patients. (C) 2013 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available